Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
JACC Cardiovasc Interv
; 6(8): 777-89, 2013 Aug.
Article
en En
| MEDLINE
| ID: mdl-23968698
ABSTRACT
OBJECTIVES:
This study sought to report the final 5 years follow-up of the landmark LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) trial.BACKGROUND:
The LEADERS trial is the first randomized study to evaluate biodegradable polymer-based drug-eluting stents (DES) against durable polymer DES.METHODS:
The LEADERS trial was a 10-center, assessor-blind, noninferiority, "all-comers" trial (N = 1,707). All patients were centrally randomized to treatment with either biodegradable polymer biolimus-eluting stents (BES) (n = 857) or durable polymer sirolimus-eluting stents (SES) (n = 850). The primary endpoint was a composite of cardiac death, myocardial infarction (MI), or clinically indicated target vessel revascularization within 9 months. Secondary endpoints included extending the primary endpoint to 5 years and stent thrombosis (ST) (Academic Research Consortium definition). Analysis was by intention to treat.RESULTS:
At 5 years, the BES was noninferior to SES for the primary endpoint (186 [22.3%] vs. 216 [26.1%], rate ratio [RR] 0.83 [95% confidence interval (CI) 0.68 to 1.02], p for noninferiority <0.0001, p for superiority = 0.069). The BES was associated with a significant reduction in the more comprehensive patient-orientated composite endpoint of all-cause death, any MI, and all-cause revascularization (297 [35.1%] vs. 339 [40.4%], RR 0.84 [95% CI 0.71 to 0.98], p for superiority = 0.023). A significant reduction in very late definite ST from 1 to 5 years was evident with the BES (n = 5 [0.7%] vs. n = 19 [2.5%], RR 0.26 [95% CI 0.10 to 0.68], p = 0.003), corresponding to a significant reduction in ST-associated clinical events (primary endpoint) over the same time period (n = 3 of 749 vs. n = 14 of 738, RR 0.20 [95% CI 0.06 to 0.71], p = 0.005).CONCLUSIONS:
The safety benefit of the biodegradable polymer BES, compared with the durable polymer SES, was related to a significant reduction in very late ST (>1 year) and associated composite clinical outcomes. (Limus Eluted From A Durable Versus ERodable Stent Coating [LEADERS] trial; NCT00389220).Palabras clave
ACS; ARC; Academic Research Consortium; BES; BMS; CI; DES; KM; Kaplan-Meier; MACE; MI; PCI; POCE; RR; SES; ST; ST-segment elevation myocardial infarction; STEMI; TVR; acute coronary syndrome; bare-metal stent(s); biodegradable polymer; biolimus-eluting stent(s); confidence interval; drug-eluting stent(s); drug-eluting stents; durable polymer; major adverse cardiac events; myocardial infarction; patient-oriented composite endpoint; percutaneous coronary intervention; rate ratio(s); sirolimus-eluting stent(s); stent thrombosis; target vessel revascularization
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Polímeros
/
Enfermedad de la Arteria Coronaria
/
Trombosis Coronaria
/
Fármacos Cardiovasculares
/
Sirolimus
/
Implantes Absorbibles
/
Stents Liberadores de Fármacos
/
Intervención Coronaria Percutánea
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Europa
Idioma:
En
Revista:
JACC Cardiovasc Interv
Asunto de la revista:
ANGIOLOGIA
/
CARDIOLOGIA
Año:
2013
Tipo del documento:
Article
País de afiliación:
Países Bajos